



# Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 29 April 2024

Ref. No.: TCPCL/SEC/2024-25/00007

**To,**  
**The General Manager,**  
**Corporate relationship department,**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

**The Manager,**  
**Listing department,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex, Bandra(E),  
Mumbai-400 051

**Scrip Code: 543321**

**Scrip Symbol: TATVA**

**Subject: Fund raising by issuance of debt securities by Large Corporates**

**Ref.: Chapter XII of SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.**

Dear Sir/Madam,

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, we hereby confirm that Tatva Chintan Pharma Chem Limited is not a Large Corporate as per the applicability criteria given under the above mentioned SEBI circulars.

The details as required in respect of Initial Disclosure are enclosed as Annexure - XII – A.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,  
**For Tatva Chintan Pharma Chem Limited**

**Ishwar Nayi**  
**Company Secretary and Compliance Officer**  
**M. No.: A37444**

Encl.: As above

**Annexure - XII – A**

**Format of the Initial Disclosure to be made by an entity identified as a Large Corporate**  
(To be submitted to the Stock Exchange(s) within 30 days from the beginning of the FY)

Sr. No.	Particulars	Details
1.	Name of the Company	<b>TATVA CHINTAN PHARMA CHEM LIMITED</b>
2.	CIN	<b>L24232GJ1996PLC029894</b>
3.	Outstanding borrowing of company as on 31 March 2024, as applicable (in Rs. crore)	<b>Rs. 4.27 Crores</b>
4.	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	<b>CRISIL A-/Stable (Long Term Rating)</b> <b>CRISIL A2+ (Short Term Rating)</b>
		<b>Agency – CRISIL Ratings Limited</b>
5.	Name of stock exchange* in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	<b>Not Applicable</b>

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as updated on April 13, 2022 and SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.

**For Tatva Chintan Pharma Chem Limited**

\_\_\_\_\_  
**Ishwar Nayi**  
**Company Secretary**  
**M. No.: A37444**  
Tel: +91 75748 48533  
E-mail: cs@tatvachintan.com

\_\_\_\_\_  
**Ashok Bothra**  
**Chief Financial Officer**  
Tel: +91 75748 48533  
E-mail: finance@tatvachintan.com

Date – 29/04/2024

\*Note: In terms paragraph of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.